DESIGN AND EVALUATION OF NIFEDIPINE FLOATING MATRIX TABLETS

Rohit Jaimini1, Dr. Mayank Bansal2
1Research Scholar, Department of Pharmaceutics, Jaipur College of Pharmacy, Jaipur, Rajasthan, India
2Professor and Principal, Jaipur College of Pharmacy, Jaipur, Rajasthan, India

Article Info: Received 17 February 2020; Accepted 28 March 2020
DOI: https://doi.org/10.32553/jbpr.v9i2.730
Address for Correspondence: Rohit Jaimini
Conflict of interest statement: No conflict of interest

ABSTRACT:
Floating drug delivery systems are retained in the stomach and are useful for drugs that are poorly soluble or unstable in intestinal fluid. Floating drug delivery system have a bulk density less than that of gastric fluids and so remain buoyant in the stomach without affecting the gastric emptying rate for a prolong period of time. Research work emphasized on design and evaluates nifedipine floating matrix tablets in which polymers i.e. hydroxypropyl methyl cellulose (HPMC K100M, K4, and K15) was used. About 15-35 % of HPMC can be used as a polymer in the extended release formulations. So, here the polymer was used in the range of 16-36 %. Sodium bicarbonate (40%) is used as a gas generating agent. It can be used in the range of 25-50 %. The granules are prepared by wet granulation method. The prepared granules were evaluated for the bulk density, tapped density, bulkiness, angle of repose, compressibility index and hausner ratio. The values indicate good flow property. The compressed tablets were evaluated for hardness, uniformity of weight, friability, drug content, buoyancy lag time and duration of buoyancy. All the readings are within the prescribed limits. There was no interaction between the drug, polymer and excipients it was found out by IR studies. The in vitro drug release data indicate that the release of the drug depends upon the proportion of polymer present in the formulation. As the polymer ratio increases the release rate of the drug is prolonged.

Keywords: Floating tablet, HPMC K100M, nifedipine, HPMC K4

Introduction
Several difficulties are faced in designing controlled release systems for better absorption and enhanced bioavailability. One of such difficulties is the inability to confine the dosage form in the desired area of the gastrointestinal tract. Drug absorption from the gastrointestinal tract is a complex procedure and is subject to many variables. It is widely acknowledged that the extent of gastrointestinal tract drug absorption is related to contact time with the small intestinal mucosa. Thus, small intestinal transit time is an important parameter for drugs that are incompletely absorbed. Floating drug delivery system have a bulk density less than that of gastric fluids and so remain buoyant in the stomach without affecting the gastric emptying rate for a prolong period of time. While the system is floating on the gastric contents, the drug is released slowly at the desired rate from the system. After release of drug, the residual system is emptied from the stomach. This result in an increased GRT and a better control of fluctuation in plasma drug concentration.

Materials and Methods:

Table 1: The chemical and solvent used in the present investigation

| S. No. | NAME         | Supplier / Manufacturer                  |
|-------|--------------|------------------------------------------|
| 1     | Nifedipine   | Unichem laboratories Ltd, Mumbai         |
| 2     | HPMC K4 M    | Anil Enterprises, Delhi                  |
| 3     | HPMC K15 M   | samson laboratories pvt. ltd, solan himachal Pradesh |
| 4     | HPMC K100 M  | samson laboratories pvt. ltd, solan himachal Pradesh |
| 5     | Sodium bicarbonate | Central drug house p.ltd, New Delhi   |
| 6     | Lactose      | Loba chemie Pvt. Ltd-Mumbai             |
| 7     | Ethyl Cellulose | Loba chemie Pvt. Ltd-Mumbai             |
| 8     | Talc         | Loba chemie Pvt. Ltd-Mumbai             |
| 9     | Magnesium Stearate | Loba chemie Pvt. Ltd-Mumbai           |
| 10    | Poly propyl alcohol | from Nice chemicals Pvt. Ltd-Cochin |
| 11    | Starch       | Loba chemie Pvt. Ltd-Mumbai             |

Table 2: List of instruments and equipments

| S. No. | Name                       | Manufacturer with model |
|-------|---------------------------|-------------------------|
| 1     | Melting point Apparatus   | Macro Scientific works, 603 |
| 2     | Digital Weighing Balance  | Fisher brand, PS-200    |
| 3     | Double beam UV Spectrophotometer | Systronics 2203          |
| 4     | Differential scanning Calorimeter(DSC) | Perkin Elmer,Pyris, DSC, USA |
| 5     | Infra Red Spectrophotometer | Shimadzu FTIR,3300     |
| 6     | Incubator                 | Instrument India, Mumbai |
| 7     | Six Basket Dissolution Apparatus | Lab India DT 8000         |
| 8     | Magnetic stirrer          | Instrument India, Mumbai |
| 9     | Heating mental            | Instrument India, Mumbai |
| 11    | pH meter                  | Instrument India, Mumbai |
| 12    | Tablet machine            | Shakti Pharma Tech, Gujrat |
Calibration Curve of Nifedipine:

Principle: The calibration curve is based on the spectrophotometry. The maximum absorption was observed at 350nm. It obeyed Beer’s law in the concentration range of 2-20µg/ml.

Standard stock solution:

The stock solutions were freshly prepared by dissolving 100mg of nifedipine in a 100ml volumetric flask and then make up the solution up to the mark using 0.1N HCl for obtaining the solution of strength 1000 µg/mL (stock I). 10ml of this solution is diluted to 100ml with 0.1N HCl to obtain a solution of strength 100 µg/mL (stock II). From this secondary stock required concentrations 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20µg/mL was prepared. The absorbance was measured at 350 nm using a UV spectrophotometer.

Preparation of Nifedipine floating matrix tablets:

Tables containing Nifedipine were prepared by wet granulation method. The respective powders drug, polymers (HPMC K4M, HPMC K 15M, HPMC K100M), sodium bicarbonate, lactose were blended thoroughly with mortar and pestle. The powder blend was then lubricated with magnesium stearate and talc mixed for about 3 minutes. The required amount of the blend was weighed and finally this mixture was compressed on a 10-station rotary tablet machine using 10-mm standard flat-face punches

**Table 3: Preparation of floating tablet of Nifedipine**

| Formulation | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|-------------|---|---|---|---|---|---|---|---|---|----|
| HPMC K4M(mg) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| HPMC K15M(mg) | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| HPMC K100M(mg) | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
| Citric acid(mg) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Tartaric acid(mg) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Bicarbonate(mg) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| K100M(mg) | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 |
| HPMC K4M(mg) | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
| Lactose | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Talc | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Magn. Stereo | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |

**EVALUATION OF NIFEDIPINE FLOATING GRANULES:**

Preformulation studies of powder drug of nifedipine performed according to standard procedure given in IP 1996 i.e. Angle of repose, Bulk density, Tapped density, Bulkiness: Compressibility index and hausner ratio.

**EVALUATION OF NIFEDIPINE FLOATING TABLETS:**-

**Tablet thickness:**

The thickness in millimeters (mm) was measured individually for 10 pre weighed tablets by using vernier calipers. The average thickness and standard deviation were reported.

**Weight variation:**

Twenty (20) tablets from each batch were individually weighed in grams (gm) on an analytical balance. The average weight and standard deviation were calculated and the results were expressed as compliance or non-compliance of set limits.

**Hardness of the tablets:**

Ten tablets were measured in the hardness examination. Tablet hardness was measured using a Monsanto hardness tester.

**Friability of the tablets:**

Twenty tablets of the formulation were weighed and measured in a Roche type friabilator.

**The floating lag time and the total floating time:**

This test was characterized by floating lag time and total floating time. The test was performed using USP XXIII type II paddle apparatus using 900 ml of 0.1 N HCl at paddle rotation of 50 rpm at 37 ± 0.5o C. The time required for tablet to rise to surface of dissolution medium and duration of time the tablet constantly float on dissolution medium was noted as floating lag time and total floating time.

**Water uptake studies:**

The swelling behavior of dosage unit can be measured either by studying its dimensional changes, weight gain or water uptake. The water uptake study of the dosage form was conducted by using USP dissolution apparatus-II in a 900ml of distilled water which was maintained at 37o ± 0.5oc, rotated at 50 rpm. At selected regular intervals the tablet was withdrawn and weighed. Percentage swelling of the tablet was expressed as percentage water uptake (%WU).

\[ \%WU = \frac{Wt - Wo}{Wo} \times 100 \]

Where Wt is the weight of the swollen tablet and Wo is the initial weight of the tablet.

**Drug–excipients interaction studies:**

The infrared spectra of pure drug, physical mixture of drug and excipients, polymer and formulation were recorded between 4000 to 400 cm⁻¹ on FTIR.

**Dissolution Study of tablets:**

The tablet was placed inside the dissolution vessel. 5ml of sample were withdrawn at time intervals of 0.5, 1, 2, 3, 4, 6, 8, 10 and 12h. The volume of dissolution fluid adjusted to 900 ml by replacing 5ml of dissolution medium after each sampling. The release studies were
conducted with 3 tablets, & the mean values were plotted versus time. Each sample was analyzed at 301 nm using double beam UV and Visible Spectrophotometer against reagent blank. The drug concentration was calculated using standard calibration curve.

RESULTS AND DISCUSSION:

Differential scanning calorimetry

The sample preparations are sealed in aluminum pan and heated at constant ratio of 10°C/min over a temperature range of 25°C - 65°C.

Table 4: Determination of UV absorbance maxima of Nifedipine:

| Conc. (ug/ml) | Absorbance |
|--------------|------------|
| 0            | 0.000      |
| 2            | 0.121      |
| 4            | 0.242      |
| 6            | 0.355      |
| 8            | 0.468      |
| 10           | 0.585      |
| 12           | 0.651      |
| 14           | 0.761      |
| 16           | 0.821      |
| 18           | 0.910      |
| 20           | 1.012      |

Table 5: Evaluation of Nifedipine granules for formulation

| Parameter                  | Angle of Repose(θ) | Bulk Density (mg/ml) | Tapped Density (mg/ml) | Hausner Ratio | Compressibility Index (%) |
|----------------------------|--------------------|----------------------|------------------------|---------------|---------------------------|
| Formulation                | 21                 | 25.827±1.675         | 0.673±0.010            | 0.776±0.029   | 1.152±0.023               | 13.265±1.672 |
|                            | 22                 | 26.406±1.203         | 0.589±0.023            | 0.666±0.031   | 1.131±0.025               | 11.607±1.262 |
|                            | 23                 | 25.900±1.109         | 0.628±0.031            | 0.702±0.028   | 1.117±0.027               | 10.476±1.623 |
|                            | 24                 | 28.885±1.576         | 0.661±0.028            | 0.758±0.039   | 1.149±0.031               | 13.065±1.213 |
|                            | 25                 | 26.575±1.320         | 0.611±0.033            | 0.717±0.027   | 1.148±0.008               | 12.962±1.278 |
|                            | 26                 | 25.706±0.923         | 0.634±0.007            | 0.634±0.018   | 1.130±0.023               | 11.538±1.291 |
|                            | 27                 | 28.071±1.328         | 0.568±0.025            | 0.653±0.016   | 1.115±0.032               | 10.344±1.328 |
|                            | 28                 | 27.348±1.134         | 0.584±0.027            | 0.640±0.026   | 1.118±0.039               | 10.619±1.259 |
|                            | 29                 | 26.706±0.914         | 0.573±0.031            | 0.694±0.023   | 1.157±0.029               | 10.434±1.306 |
|                            | 30                 | 26.565±0.973         | 0.603±0.008            | 0.660±0.013   | 1.150±0.011               | 13.636±2.018 |
|                            | 31                 | 28.787±1.004         | 0.573±0.023            | 0.680±0.036   | 1.134±0.028               | 11.818±0.775 |
|                            | 32                 | 28.298±1.281         | 0.667±0.032            | 0.715±0.031   | 1.29±0.031                | 11.447±1.243 |

Table 6: Post compression evaluation of nifedipine tablets

| Formula code | Weight variation(mg) | Hardness kg/cm² | Thickness (mm) | Friability (%) | Lag time (sec) |
|--------------|----------------------|-----------------|----------------|----------------|----------------|
| 21           | 347±2.3              | 44±0            | 3.21±0.08      | 0.26           | 30             |
| 22           | 351±3.8              | 44±0            | 3.23±0.06      | 0.23           | 39             |
| 23           | 356±4.5              | 44±0            | 3.21±0.06      | 0.48           | 20             |
| 24           | 358±8.3              | 44±0            | 3.22±0.09      | 0.51           | 30             |
| 25           | 345±5.3              | 44±0            | 3.26±0.08      | 0.22           | 18             |
| 26           | 349±2.3              | 44±0            | 3.21±0.05      | 0.41           | 12             |
| 27           | 353±5.5              | 44±0            | 3.24±0.05      | 0.35           | 10             |
| 28           | 344±5.6              | 44±0            | 3.28±0.02      | 0.38           | 14             |
| 29           | 348±3.3              | 44±0            | 3.23±0.02      | 0.41           | 32             |
| 30           | 346±6.2              | 44±0            | 3.21±0.16      | 0.29           | 21             |
| 31           | 351±4.3              | 44±0            | 3.28±0.05      | 0.38           | 7              |
| 32           | 349±2.3              | 44±0            | 3.19±0.09      | 0.41           | 12             |
**Table 7:** Swelling index studies of Nifedipine floating tablets

| Time (hr) | Z1 | Z2 | Z3 | Z4 | Z5 | Z6 | Z7 | Z8 | Z9 | Z10 | Z11 | Z12 |
|-----------|----|----|----|----|----|----|----|----|----|-----|-----|-----|
| 0         | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0    | 0    | 0    |
| 2         | 32 | 35 | 35 | 42 | 36 | 38 | 35 | 38 | 36 | 39   | 35   | 34   |
| 4         | 46 | 48 | 48 | 50 | 49 | 55 | 45 | 48 | 63 | 65   | 62   | 52   |
| 6         | 52 | 55 | 55 | 58 | 62 | 78 | 54 | 59 | 73 | 75   | 72   | 65   |
| 8         | 63 | 70 | 70 | 72 | 76 | 89 | 64 | 68 | 84 | 85   | 82   | 72   |
| 10        | 88 | 91 | 88 | 91 | 99 | 110| 74 | 79 | 99 | 102  | 110  | 98   |
| 14        | 108| 112| 112| 113| 128| 138| 142| 139| 135| 140  | 135  | 139  |
| 18        | 140| 135| 130| 155| 180| 177| 172| 181| 160| 165  | 162  | 174  |

**DRUG RELEASE STUDIES:**

**Table 8:** In vitro release data of nifedipine – Zero-order release

| Time (hr) | Z1 | Z2 | Z3 | Z4 | Z5 | Z6 | Z7 | Z8 | Z9 | Z10 | Z11 | Z12 |
|-----------|----|----|----|----|----|----|----|----|----|-----|-----|-----|
| 0         | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0    | 0    | 0    |
| 2         | 24.23|22.35|12.75|21.15|
| 4         | 35.45|26.21|32.56|34.15|
| 8         | 37.45|37.51|47.21|46.12|
| 12        | 45.48|48.24|64.23|52.12|
| 16        | 65.45|51.12|72.12|72.12|
| 18        | 77.25|67.25|84.29|78.31|

**Figure 3:** Zero order release profile of Nifedipine

**Table 9:** In vitro release data of nifedipine – First-order release

| Time (hr) | Z1 | Z2 | Z3 | Z4 | Z5 | Z6 | Z7 | Z8 | Z9 | Z10 | Z11 | Z12 |
|-----------|----|----|----|----|----|----|----|----|----|-----|-----|-----|
| 0         | 2  | 2  | 2  | 2  | 2  | 2  | 2  | 2  | 2   | 2    | 2    | 2    |
| 2         | 1.87|1.89|1.94|1.89|
| 4         | 1.80|1.86|1.82|1.81|
| 8         | 1.79|1.79|1.72|1.73|
| 12        | 1.73|1.71|1.55|1.68|
| 16        | 1.53|1.68|1.44|1.44|
| 18        | 1.35|1.51|1.19|1.33|
**Figure 4:** First order drug release profile of Nifedipine

**Table 10:** Fit of various kinetic models for floating tablet of nifedipine

| Formulation code | Zero order R2 | First order R2 | Higuchi model R2 | Korsemeyer model R² |
|------------------|---------------|----------------|------------------|---------------------|
| Z1               | 0.949         | 0.932          | 0.966            | 0.756               |
| Z2               | 0.921         | 0.956          | 0.970            | 0.766               |
| Z3               | 0.966         | 0.956          | 0.980            | 0.745               |
| Z4               | 0.949         | 0.938          | 0.980            | 0.754               |
| Z5               | 0.965         | 0.963          | 0.970            | 0.831               |
| Z6               | 0.957         | 0.980          | 0.990            | 0.830               |
| Z7               | 0.966         | 0.874          | 0.988            | 0.831               |
| Z8               | 0.957         | 0.874          | 0.970            | 0.831               |
| Z9               | 0.963         | 0.878          | 0.947            | 0.794               |
| Z10              | 0.955         | 0.972          | 0.958            | 0.794               |
| Z11              | 0.955         | 0.972          | 0.958            | 0.793               |
| Z12              | 0.956         | 0.946          | 0.948            | 0.836               |

**Conclusion:**

Drug delivery system should deliver drug at a dictated by needs of the body over a specified period of time. The newer drug delivery system is being used to body distribution of drug with a view to reduce the toxicity of drug and deliver to their site of action. Floating drug delivery systems are retained in the stomach and are useful for drugs that are poorly soluble or unstable in intestinal fluid. Floating drug delivery system have a bulk density less than that of gastric fluids and so remain buoyant in the stomach without affecting the gastric emptying rate for a prolong period of time. About 15-35 % of HPMC can be used as a polymer in the extended release formulations. So, here the polymer was used in the range of 16-36 %. Sodium bicarbonate (40%) is used as a gas generating agent. It can be used in the range of 25-50 %. The granules are prepared by wet granulation method. The prepared granules were evaluated for the bulk density, tapped density, bulkiness, angle of repose, compressibility index and hausner ratio. The values indicate good flow property. The compressed tablets were evaluated for hardness, uniformity of weight, friability, drug content, buoyancy lag time and duration of buoyancy. All the readings are within the prescribed limits.

**References:**

1. Agarwal M, Srinivasan R, Mishra A. A study on flocculation efficiency of okra gum in sewage waste water. Macromol Mat Eng 2001;9:560-63.
2. Singh B. Psyllium as therapeutic and drug delivery agent. Int J Pharm 2007; 334: 1–14.
3. Singh K, Kumar A, Langyan N, Ahuj M. Evaluation of Mimosa pudica Seed Mucilage as Sustained-Release Excipient. AAPS PharmSciTech 2009; 10(4):1121
4. Petropoulos GA. Fenugreek: The genus Trigonella. In: Petropoulus GA, (Ed.), Botany. London: Taylor and Francis; 2002.9–17.
5. A.O. Nur, and J. S. Zhang, Captopril floating and/or bioadhesive tablets: design and release kinetics, Drug. Dev. Ind. Pharm, 26: 965 – 969, (2000).
6. E. Rudnic, and J. B. Schwartz, Oral solid dosage forms In: Remington’s Pharmaceutical Sciences. 18th Edition, Ed. Gennaro, A. R. Mack Publishing Company, Easton, Pennsylvania, USA, 1633-1665 (1990).
7. V. Iannucelli, G. Coppi, MT. Bernabei, and R. Cameroni. Air compartment multiple-unit system for prolonged gastric residence. Part I. Formulation study, Int. J. Pharm. 174: 47-54 (1998).
8. Sood A and Panchaghula R: Design of controlled release delivery systems using modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index, Int. J. Pharm, 2003; 261: 27 –41.
9. Hwang SJ, Park H, and Park K: Gastric retentive drug delivery systems, Crit Rev Ther Drug, 1998; 15: 243 – 348.